

Blackstone to acquire AYUMI Pharmaceutical

18 March 2019 | News

The acquisition would mark Blackstone's first control private equity investment in Japan



Blackstone has announced that private equity funds managed by Blackstone have entered into a definitive agreement to acquire AYUMI Pharmaceutical Corporation, pharmaceutical company in Japan focused on Anti-Rheumatism and Orthopedics, from Unison Capital, an independent private equity firm based in Japan, and M3, Inc., a medical information site business.

Atsuhiko Sakamoto, Senior Managing Director and Head of Japan Private Equity at Blackstone, commented: “We are delighted to announce our new partnership with AYUMI. Under the leadership of its seasoned management team, AYUMI has established a robust foundation as a leading specialty pharmaceutical company in the field of rheumatism and orthopedics – with world-class medical and scientific capabilities. We look forward to working with the Company to leverage Blackstone’s global footprint and expertise in this sector to help AYUMI meet the growing need for its RA and orthopedic products, invest in new, cutting-edge treatments and products, and continue supporting the Company’s mission of improving patient health.”

Ouchi Hikaru, Representative Director, President and CEO of AYUMI, commented: “It is a great honor to announce our new partnership with Blackstone to further accelerate our growth. Although we have already established a strong platform of growth in partnership with Unison Capital, from orthopedic therapeutic areas to RA areas and further through the new introduction of biosimilar products, we will need more investment for future growth. We have great expectations for our new shareholder in order to further enhance our presence in the Japanese pharmaceutical industry and to continue providing drug treatments that contribute to patients and to society.

The acquisition would mark Blackstone’s first control private equity investment in Japan. The transaction is expected to close in the second quarter of 2019, subject to regulatory approvals and customary closing conditions.